^
    Back
    Association details:
    Biomarker:PIK3CA Q75E
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Invest
    Title:

    Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma

    Published date:
    11/15/2021
    Excerpt:
    We report a patient with HNSCC with a noncanonical PIK3CA mutation (Q75E) who exhibited a durable (12 months) response to alpelisib in a phase II clinical trial....Clinical response to alpelisib of a patient with HNSCC harboring the noncanonical PIK3CA mutation Q75E….The patient was treated for a total of 12 months with single-agent alpelisib until his disease progressed, and he was switched to durvalumab...He is currently alive with stable disease on durvalumab, approximately 2 years after completing alpelisib monotherapy.
    DOI:
    10.1172/JCI150335